Latest Headlines

31. Onchilles Pharma Announces IND Clearance For N17350, Advancing The First Next-Generation Cytotoxic Therapeutic Leveraging The ELANE Pathway Into The Clinic 2/2/2026

    Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for N17350 to initiate first-in-human clinical studies in patients with advanced solid tumors.

32. Frontage Laboratories Expands Early Phase Clinical Capabilities To Support Global Drug Development 1/30/2026

    Frontage Laboratories, Inc. ("Frontage"), a global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the expansion of its early phase clinical research capabilities across the United States and China. This strategic growth enhances the company's ability to support pharmaceutical and biotech partners with accelerated, high‑quality clinical development solutions.

33. VoxCell Appoints Chief Commercial Officer As Demand Grows For Predictive, Human-Relevant, Non-Clinical Testing Approaches 1/29/2026

    New appointment strengthens commercial leadership as regulatory momentum builds for alternative non-animal models for new drug and biological product applications.

34. DiMe Introduces Core Digital Measures Set To Accelerate Drug Development For Pediatric Rare Diseases 1/29/2026

    The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) today announced the launch of the first core set of digital clinical measures for pediatric rare diseases, a toolkit created to address the stark reality that 95% of rare diseases have no disease modifying treatment or cure, leaving most children with rare and ultra-rare conditions without disease-modifying therapies and their families without hope.

35. SGD Pharma Leads Pharma Packaging Innovation And Decarbonization At PharmaPack Europe 2026 1/28/2026

    SGD Pharma, a global market leader in pharmaceutical glass primary packaging and the leader of its industry on sustainability, will showcase its latest advancements in high-performance solutions at Pharmapack Europe, taking place in Paris on 21^st to 22^nd January 2026.

36. Unravel Biosciences And The SCN2A Foundation Announce Drug Discovery Collaboration 1/28/2026

    The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics company established to advance drugs for complex diseases.

37. Insilico Medicine And Qilu Pharmaceutical Reach Near $120M Drug Development Collaboration To Accelerate Novel Cardiometabolic Therapies 1/27/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center, today announced a strategic partnership on innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

38. Drug Farm Announces FDA Fast Track Designation For First-In-Class ALPK1 Inhibitor DF-003 For The Treatment Of ROSAH Syndrome 1/27/2026

    Drug Farm, a clinical-stage biopharmaceutical company advancing two novel small molecule drugs for ROSAH syndrome and hepatitis B, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DF-003, its investigational, first-in-class ALPK1 inhibitor, for the treatment of ROSAH syndrome, a rare, autosomal dominant autoinflammatory disease with no approved therapies.

39. Mair Therapeutics Announces Scientific Collaboration With Radboud University To Advance TMEM175 Agonists For Parkinson's Disease 1/26/2026

    Mair Therapeutics, a Dutch biotechnology company pioneering lysosomal-targeted therapies for neurodegenerative diseases, today announced a scientific collaboration with Radboud University to accelerate the discovery of small-molecule agonists of TMEM175, a lysosomal ion channel genetically linked to Parkinson's disease.

40. Lunai Bioworks Expands NIH-Funded AI Program Into Commercial Alcohol Use Disorder Drug Discovery 1/26/2026

    Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal.